Play ButtonClose ButtonCheck IconLogo Genethics FooterMail IconMessage IconPhone IconUser IconArrowArrow leftArrow right

Included in the clinical guidelines of

ASCO 2017

Included in the clinical guidelines of the International Congress of

St. Gallen 2017

Included in the

Oncology Clinics of Iberoamerica

Randomized phase 3 study that grants Mammaprintel level of clinical evidence 1A

MINDACT

There are no

intermediate results

Clinical Criteria

Diagnosis of breast cancer

Stage

I - IIB

Receptors

ER +/-
PR +/-
Her2 -

Type of sample
Tissue samples
Paraffin

Ganglia

Up to 3 +

Size

< 2 in

Result time
10 to 15 days
Paraffin

Benefits of Mammaprint®

· Number of genes.

70

· Number of control genes.

465

· FDA 510 (k) approved for women of all ages.

Yes

· FDA 510 (k) approved for ER positive and negative.

Yes

· Independent results of endocrine therapy (tamoxifen or Al) treatment compliance for 5 days.

· Stable test for patients with metabolic syndrome (obesity, diabetes and HTN).

· Definitive classification of high and low risk.

· Widely reimbursed in USA and the world.

· Test available to make molecular subtypes.

· Developed independently of clinical pathological factors.

Yes

Request a test